CHLA Clinical Research Studies
Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.
By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.
In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.
Please contact the study staff listed in your search results for more information.
Back to the full listing
|Study Details - ID: CHLA-19-00158|
Type 1 Diabetes (T1D)
|Full Title of Study:|
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with and Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes
|Phase/Type of Study:|
|Purpose of Research:|
To demonstrated that an ultra-fast-acting formulation of insulin lispro is non-inferior to Humalog on measures of glycemic control when administered 0 to 2 minutes before eating in combination with basal insulin.
Children between ages 1 to <18 years of age with an HbA1c ≥6.5% but ≤9.5%, not currently on an insulin pump, and willing to test between 4-7 times per day even if using CGM.
Seven clinic visits and nine phone visits over 33 weeks. Initial visits within 1-3 weeks of each other, then every 6 weeks. Reimbursement provided for travel and other expenses: $100 per clinic visit and $25 per phone visit.
Roshanak Monzavi, MD
|Coordinator Contact Name:|
Dan Brimberry, PhD / Debra Miller, BSN, CDE
|Clinical Trials .Gov Identifier:NCT03740919|